Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Accumulated Expenses (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Accumulated Expenses for 4 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 160.19% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 160.19% increase, with the full-year FY2025 number at $794836.0, changed N/A from a year prior.
  • Accumulated Expenses was $2.1 million for Q4 2025 at Neuphoria Therapeutics, up from $497667.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.1 million in Q4 2025 to a low of $305452.1 in Q2 2023.
  • A 4-year average of $853938.1 and a median of $794358.5 in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 65.31% in 2023, then soared 160.19% in 2025.
  • Neuphoria Therapeutics' Accumulated Expenses stood at $880579.6 in 2022, then plummeted by 65.31% to $305452.1 in 2023, then surged by 159.9% to $793881.0 in 2024, then skyrocketed by 160.19% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Accumulated Expenses are $2.1 million (Q4 2025), $497667.0 (Q3 2025), and $794836.0 (Q2 2025).